Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use
Haematologica. 2021 Jun 1;106(6):1767-1769.
doi: 10.3324/haematol.2020.260133.
1 CHU Lille, Laboratory of Hematology, F-59000 Lille.
2 Hospices Civils de Lyon, Lyon-Sud University Hospital, Department of Hematology, Lyon.
3 CHU Lille, Laboratory of Hematology, F-59000 Lille, FRANCE; Univ. Lille, CNRS, Inserm, CHU Lille, Institut de Recherche contre le Cancer de Lille, UMR9020 - UMR-S 1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille.
4 AP-HP, Saint-Louis Hospital, Department of Hematology, Saint-Louis Research Institute, Université de Paris, Paris.
5 Gustave Roussy Institute, Department of Hematology, Villejuif.
6 Toulouse Cancer University Institute, Department of Hematology, Toulouse.
7 CH Versailles, Department of Hematology, Le Chesnay.
8 Univ. Lille, CNRS, Inserm, CHU Lille, Institut de Recherche contre le Cancer de Lille, UMR9020 - UMR-S 1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, FRANCE; CHU Lille, Department of Clinic Hematology, F-59000 Lille.
9 Bordeaux Haut-Lévêque University Hospital, Department of Hematology, Pessac.
10 CHU Limoges, Univ. Limoges, Department of Hematology, Limoges.
11 AP-HP, Department of Hematology, Henri Mondor Hospital, Créteil.
12 Curie Hospital, René Huguenin Hospital, Saint-Cloud.
13 CHU Lille, Laboratory of Hematology, F-59000 Lille, FRANCE; Univ. Lille, CNRS, Inserm, CHU Lille, Institut de Recherche contre le Cancer de Lille, UMR9020 - UMR-S 1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille. [email protected].